The ASCEND-CRC trial is part of an ADAPT program framework aimed at aligning cancer therapies with real-time tumor evolution in metastatic colorectal cancer. The initiative seeks to move beyond single pre-treatment biomarkers by employing multimodal profiling to longitudinally monitor tumor evolution and uncover early adaptive mechanisms that precede resistance.
By identifying dynamic biomarkers that are actionable for treatment decisions, the study aims to guide therapeutic choices as tumors evolve rather than rely on static, baseline assessments. The overarching goal is to establish a scalable platform for intercepting resistance by integrating ongoing tumor profiling into clinical decision-making.
Uncertainty remains regarding the specific biomarkers, methods, and interim outcomes to date, as the available description emphasizes objectives and conceptual approach rather than validated results. The ASCEND-CRC framework is presented as a component of broader ADAPT efforts intended to transform precision oncology and improve the ability to tailor therapies to evolving tumor biology.